Mayo Clinic Tests Radiation for Parkinson's Treatment
Researchers in Rochester are launching a clinical trial to evaluate if low-dose radiation therapy can slow Parkinson's disease.
Updated on Oct. 21, 2026 in Stroke
Live Poll
Should medical researchers prioritize testing existing therapies on different diseases to find potential new treatments?
Mayo Clinic researchers have initiated a clinical trial testing low-dose radiation therapy to treat early-stage Parkinson's disease. The study aims to determine if this approach can reduce inflammation and slow the progression of symptoms associated with the condition.
Why it matters
By targeting brain inflammation, this therapy seeks to address underlying biological processes in patients who have lost dopamine-producing cells. The trial represents an experimental effort to intervene in the disease's progression before symptoms advance significantly.
The clinical trial will enroll 20 participants between the ages of 45 and 75. Patients will receive daily low-dose radiation sessions for five consecutive days, with each treatment lasting between 10 and 15 minutes.
The players
Mayo Clinic
A nonprofit American academic medical center focused on integrated health care, education, and research based in Rochester, Minnesota.
The details
Researchers utilize brain imaging to map anatomy and pinpoint radiation delivery sites for each subject. The trial focuses on patients with early-stage Parkinson's while specifically excluding those with disease associated with a known genetic cause.
Timeline
Participants receive daily treatments for five consecutive days.
Initial evaluation of biomarkers occurs six hours post-treatment.
Follow-up evaluations are scheduled at 3, 6, and 12 months.
The Big Picture
This study follows the established methodology used in the Mayo Clinic's clinical trial program to investigate non-standard interventions for neurodegenerative diseases. It shifts the focus from traditional dopamine-replacement therapies toward managing the underlying inflammatory environment of the brain.
Participation in this study is available by invitation only for qualified patients meeting the specific age and early-stage diagnostic criteria. Patients should consult with their neurology team to understand how clinical trial exclusions, such as known genetic causes, affect their eligibility.
The takeaway
Early-stage intervention remains a primary hurdle in treating Parkinson's disease due to the complexity of protein accumulation in the brain. This trial highlights the medical community's ongoing search for alternative therapies that move beyond standard symptomatic relief.
Further reading
For more information on current brain health studies, visit the Rochester Stroke section.
Live Poll
Should medical researchers prioritize testing existing therapies on different diseases to find potential new treatments?
